Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China

Core Insights - Adagene Inc. announced that its lead product ADG126 will be featured in two oral presentations at the CSCO Meeting in Jinan, China, from September 10-14, 2025 [1] Group 1: Clinical Developments - ADG126, a masked anti-CTLA-4 SAFEbody, is currently in Phase 1b/2 clinical studies in combination with pembrolizumab for treating advanced microsatellite-stable colorectal cancer (MSS CRC) [6][7] - The combination therapy has shown an objective response rate (ORR) of approximately 30% and over 80% disease control in refractory/resistant MSS CRC patients without liver metastasis, with a median overall survival (OS) of 19.4 months in the 10 mg/kg cohort [3] Group 2: Presentations at CSCO Meeting - Dr. Xu Ruihua will present updated results of the ADG126-P001 study on September 11, 2025, focusing on the efficacy of ADG126 combined with pembrolizumab in advanced MSS CRC [2] - Dr. Heinz-Josef Lenz will discuss the role of anti-CTLA-4 therapy in metastatic CRC, emphasizing the potential of ADG126 in treating cold tumors like MSS CRC [3] Group 3: Company Overview - Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies using its proprietary SAFEbody technology [4][5] - The company employs computational biology and artificial intelligence to design antibodies that meet unmet patient needs, and it has established strategic collaborations to enhance its research capabilities [4]